Comparative evaluation in an experimental model of a novel protocol of Boron Neutron Capture Therapy (BNCT) vs the standard protocol employed in clinical trials

MÓNICA A. PALMIERI, ; DEBORA N BENITEZ FRYDRYK ; YANINA LANGLE, ; EMILIANO C.C. POZZI, ; SILVIA I. THORP ; MARCELA A. GARABALINO, ; ANDREA MONTI HUGHES, ; PAULA CUROTTO, ; PAULA S. RAMOS, ; MARÍA L. PAPARELLA ; LUCAS POLTI, ; ANA EIJAN; AMANDA E. SCHWINT, ; VERÓNICA A. TRIVILLIN,

MAR DEL PLATA

Congreso; Reunion Anual de Sociedades de Biociencias SAIC-SAI-SAFIS; 2022

Boron Neutron Capture Therapy (BNCT) combines selective tumor uptake of 10B compounds and neutron irradiation. The aim of this study was to evaluate the therapeutic efficacy and radiotoxicity of (BPA/borophenylalanine+GB-10/Decahydrodecaborate)-BNCT (Comb-BNCT) alone or in combination with Oligo-Fucoidan or Glutamine, compared to the standard BPA-BNCT protocol. Also, the systemic immune response expressed in the spleen was evaluated for the Comb-BNCT group alone or in combination with Oligo-Fucoidan (O-Fuco) or Glutamine (GLN). BDIX rats were injected subcutaneously in the right hind flank with DHD/K12/TRb syngeneic colon cancer cells. Three weeks later, the tumor-bearing legs were treated locally with BNCT at the RA-3 Nuclear Reactor. a-Comb-BNCT: BPA 31 mg 10B /kg bw + GB-10 34 mg 10B/kg bw, i.v.b-Comb-BNCT+O-Fuco: same as (a) + O-Fuco (200 mg/ml) once a week for 7 weeks, joint oral and topical admin.c-Comb-BNCT+GLN: same as (a) + GLN (40 mg/ml) once a week for 7 weeks, with wet compresses.d-BPA-BNCT: 46.5 mg 10B /kg bw de BPA.e-Sham: same manipulation, no treatment.The post/pre-BNCT ratio of tumor volume at 7 weeks post treatment was significantly lower for all the groups treated with BNCT vs SHAM (p